ongo
ebola
viru
ebov
diseas
evd
epidem
western
africa
largest
evd
outbreak
record
date
requir
rapid
develop
deploy
antivir
measur
viral
glycoprotein
gp
facilit
host
cell
entri
jointli
cellular
interact
partner
constitut
potenti
target
antivir
intervent
howev
unknown
whether
gp
current
previous
circul
ebov
use
mechan
cellular
entri
thu
suscept
inhibit
antivir
cellular
defens
show
gp
ebov
circul
transduc
spectrum
target
cell
use
cellular
factor
host
cell
entri
compar
suscept
blockad
antivir
interferoninduc
transmembran
protein
neutral
antibodi
thu
virus
respons
ongo
evd
epidem
fulli
suscept
establish
antivir
strategi
target
gp
cellular
entri
factor
ebolavirus
famili
filovirida
caus
sever
frequent
fatal
diseas
human
first
document
outbreak
ebola
viru
ebov
formerli
zair
ebolaviru
diseas
evd
occur
zair
associ
casefat
rate
subsequ
evd
outbreak
record
subsaharan
africa
outbreak
gener
occur
rel
remot
area
contain
quarantin
measur
caus
maximum
case
per
outbreak
evd
outbreak
uganda
ongo
evd
epidem
origin
guinea
differ
markedli
previou
outbreak
affect
western
africa
associ
higher
death
toll
previous
record
outbreak
jointli
massiv
scale
epidem
like
due
delay
public
health
respons
howev
current
circul
virus
harbor
uniqu
amino
acid
substitut
current
unclear
whether
mutat
allow
moreeffici
spread
human
compar
virus
respons
past
outbreak
ebov
glycoprotein
gp
insert
viral
envelop
facilit
viral
entri
target
cell
moreov
gp
sole
target
neutral
antibodi
respons
gp
synthes
constitut
secretori
pathway
infect
cell
consist
surfac
unit
transmembran
unit
subunit
contain
ntermin
receptor
bind
domain
rbd
bind
host
cell
receptor
ctermin
mucinlik
domain
mld
subunit
contain
function
element
requir
fusion
viral
envelop
host
cell
membran
cellular
entri
ebov
commenc
uptak
virion
host
cell
endosom
process
promot
recognit
phosphatidylserin
viral
envelop
tim
protein
via
bridg
molecul
tam
receptor
tyrosin
kinas
axl
mer
host
cell
surfac
bind
gp
host
cell
lectin
within
endosom
cystein
proteas
remov
mld
allow
subsequ
interact
gp
cholesterol
transport
druginduc
accumul
endosom
cholesterol
block
infecti
entri
final
incomplet
character
stimulu
trigger
membran
fusion
reaction
allow
releas
ribonucleoprotein
complex
host
cell
cytoplasm
viral
cellular
factor
involv
entri
ebov
host
cell
potenti
target
antivir
intervent
howev
gp
ebov
current
circul
west
africa
harbor
uniqu
substitut
gp
unknown
whether
chang
alter
entri
cascad
andor
render
viru
resist
inhibitor
neutral
antibodi
present
studi
address
question
compar
host
cell
entri
mediat
gp
ebov
circul
adher
human
simian
cell
line
cell
cultiv
dulbecco
modifi
eagl
medium
paa
laboratori
suspens
cell
roswel
park
memori
institut
medium
paa
laboratori
supplement
fetal
bovin
serum
biochrom
antibiot
follow
cell
line
use
human
embryon
kidney
human
hepatoma
human
glioblastoma
ho
human
osteosarcoma
hela
human
cervix
carcinoma
rpe
human
retin
pigment
epitheli
eahi
human
endotheli
hybrid
raji
human
b
cell
jurkat
human
cell
human
tcellbcel
hybrid
smagi
rhesu
macaqu
mamma
carcinoma
rhesu
macaqu
kidney
vero
african
green
monkey
kidney
co
african
green
monkey
kidney
differenti
human
monocyt
macrophag
achiev
incub
pma
ngml
hour
bat
cell
line
propag
describ
elsewher
cell
grown
humidifi
atmospher
co
nucleotid
sequenc
encod
gp
current
circul
ebov
makona
variant
genbank
access
number
ebola
synthes
geneart
life
technolog
insert
via
hindiii
xbai
site
express
plasmid
gp
ebov
strain
mayinga
ebovgp
lassa
fever
viru
influenza
viru
strain
vesicular
stomat
viru
vsv
well
human
immunodefici
viru
type
mlvbase
vector
system
analysi
gpdriven
transduct
describ
elsewher
plasmid
encod
lectin
dcsign
dcsignr
lsectin
folat
receptor
also
describ
previous
monoclon
antibodi
direct
ebovgp
kindli
provid
prof
becker
marburg
monoclon
antibodi
recogn
gag
obtain
nation
institut
health
nih
aid
reagent
program
gener
retrovir
vector
pseudotyp
heterolog
viral
gp
pseudotyp
carri
describ
brief
cell
underw
calcium
phosphat
transfect
express
plasmid
encod
gp
choic
combin
plasmid
encod
gagpol
plasmid
pcswfluc
plasmid
encod
mlv
gagpol
packag
plasmid
mlvluc
cultur
supernat
harvest
hour
transfect
pass
filter
pore
size
aliquot
store
product
rhabdovir
particl
protocol
describ
elsewher
follow
vlp
produc
express
gag
combin
gp
interest
cell
follow
centrifug
vlpcontain
supernat
sucros
cushion
presenc
gag
gp
vlp
prepar
analyz
western
blot
use
antibodi
nih
monoclon
antibodi
direct
ebovgp
transduct
experi
target
cell
seed
plate
densiti
cellswel
cell
incub
hour
medium
contain
pseudoparticl
bear
gp
interest
transduct
effici
determin
quantif
luciferas
activ
cell
lysat
hour
rhabdovir
pseudotyp
hour
transduct
retrovir
pseudotyp
use
commerci
avail
kit
promega
pjk
experi
target
cell
transduc
express
interferoninduc
transmembran
ifitm
protein
transfect
express
cellular
lectin
describ
previous
transduct
gpbear
pseudotyp
altern
express
ebov
entri
factor
inhibit
small
interf
rna
sirna
sirna
knock
target
cell
perform
hour
prior
transduct
transfect
pmol
sirna
santa
cruz
use
lipofectamin
life
technolog
determin
whether
cation
amphiphil
merck
clomiphen
terconazol
sigmaaldrich
proteas
inhibitor
catl
inhibitor
iii
merck
calbiochem
sigmaaldrich
aebsf
roth
influenc
transduct
effici
inhibitor
dilut
appropri
solvent
recommend
manufactur
target
cell
preincub
inhibitor
minut
addit
pseudotyp
cultur
medium
replac
fresh
cultur
medium
without
inhibitor
hour
assess
virion
stabil
pseudotyp
bear
ebovgp
gp
vsv
vsvg
normal
compar
infect
subsequ
pseudotyp
incub
defin
temperatur
increas
period
frozen
given
time
point
use
transduct
target
cell
seventytwo
hour
transduct
transduct
effici
quantifi
luciferas
assay
pseudotyp
carri
gp
respect
ebov
isol
vsvg
control
normal
compar
infect
incub
monoclon
antibodi
indic
dilut
hour
thereaft
antibodypseudotyp
mixtur
ad
cell
cell
incub
hour
luciferas
activ
cell
lysat
determin
ebolavirus
infect
broad
spectrum
cell
type
cell
cultur
macrophag
dendrit
cell
constitut
earli
sustain
target
infect
host
contrast
lymphocyt
refractori
infect
vitro
vivo
analyz
whether
previous
current
circul
ebov
show
differ
host
cell
tropism
entri
compar
analyz
pseudotyp
bear
gp
ebov
strain
mayinga
ebovgp
ebov
variant
makona
ebovgp
differ
amino
acid
residu
rbd
amino
acid
residu
mld
supplementari
figur
pseudotyp
bear
vsvg
serv
posit
control
pseudotyp
bear
gp
use
neg
control
ebov
gp
effici
express
transfect
cell
incorpor
retrovir
particl
supplementari
figur
mediat
entri
human
cell
line
rpe
ho
eahi
compar
effici
figur
similarli
transduct
macrophag
obtain
upon
pma
treatment
cell
compar
figur
contrast
gp
unabl
facilit
transduct
human
bcell
line
raji
human
tcell
line
jurkat
human
tb
hybrid
cell
line
figur
ebov
highli
pathogen
nonhuman
primat
nhp
use
anim
model
evd
human
therefor
also
analyz
whether
ebovgp
ebovgp
transduc
nhpderiv
cell
line
transduct
smagi
cell
line
compar
transduct
vero
cell
line
figur
contrast
ebovgp
effici
ebovgp
transduc
cell
final
abil
ebovgp
ebovgp
transduc
bat
cell
line
deriv
rousettu
aegyptiacu
hypsignathu
monstrosu
examin
sinc
h
monstrosu
epomop
franqueti
myonycteri
torquata
serv
natur
reservoir
ebov
howev
appreci
differ
observ
figur
sum
result
suggest
ebov
variant
circul
exhibit
compar
cell
tropism
lectin
tam
kinas
axl
augment
entri
ebov
certain
target
cell
contrast
univers
requir
entri
dahlmann
et
al
submit
address
whether
ebovgp
ebovgp
show
differenti
depend
factor
host
cell
entri
lectin
dcsign
dcsignr
lsectin
known
augment
gpdriven
entri
promot
transduct
driven
ebovgp
ebovgp
similar
extent
express
bind
dengu
viru
effect
figur
moreov
ebovgp
ebovgp
use
axl
entri
certain
target
cell
figur
express
univers
requir
entri
figur
final
entri
driven
gp
compar
inhibit
induc
knockout
phenotyp
cell
relat
compound
figur
absenc
unwant
cytotox
effect
shown
thu
studi
reveal
obviou
differ
entri
factor
use
ebovgp
ebovgp
enzymat
activ
phdepend
endosomallysosom
cystein
proteas
cathepsin
b
catb
cathepsin
l
catl
requir
cellular
entri
pseudotyp
bear
ebovgp
authent
ebov
use
panel
inhibitor
previous
employ
studi
ebovgp
proteas
use
determin
whether
ebovgp
ebovgp
exhibit
differ
proteas
requir
entri
driven
protein
compar
inhibit
cystein
proteas
inhibitor
effici
inhibit
catb
littl
effect
catl
cat
activ
contrast
serin
proteas
inhibitor
aebsf
effect
gpdriven
entri
none
compound
test
modul
entri
driven
vsvg
figur
expect
observ
indic
ebovgp
ebovgp
depend
catb
activ
effici
transduct
cell
howev
ebovgp
less
suscept
ebovgp
blockad
third
inhibitor
catl
figur
inhibit
catb
catl
activ
similar
extent
suggest
subtl
differ
proteas
depend
gp
hivderiv
particl
rapidli
lose
infect
store
room
temperatur
loss
might
due
inactiv
viral
envelop
protein
therefor
ask
whether
retrovir
particl
bear
ebovgp
ebovgp
exhibit
differ
stabil
incub
viral
particl
bear
vsvg
ebovgp
ebovgp
hour
room
temperatur
modestli
compar
reduc
particl
infect
loss
occur
slightli
rapidli
room
temperatur
compar
figur
profound
loss
observ
upon
incub
differ
observ
ebovgp
ebovgp
figur
suggest
stabil
gp
compar
compar
inhibit
ifitm
protein
neutral
antibodi
ifitm
protein
inhibit
cellular
entri
ebov
sever
viral
pathogen
might
reduc
ebov
amplif
infect
host
rais
question
whether
virus
circul
less
suscept
ifitm
protein
inhibit
respons
outbreak
zair
engin
express
ifitm
protein
cell
appreci
impact
transduct
mediat
lassa
fever
viru
gpc
reduc
influenza
viru
hadriven
transduct
inhibit
ifitm
protein
effici
figur
keep
publish
data
transduct
ebovgp
test
also
inhibit
ifitm
protein
express
appreci
differ
inhibit
effici
observ
figur
thu
viru
host
cell
entri
ebov
inhibit
gpspecif
antibodi
neutral
antibodi
shown
exert
antivir
activ
host
assess
inhibit
ebovgp
ebovgp
entri
antibodi
obtain
evd
survivor
target
display
antivir
activ
guinea
pig
monkey
entri
driven
gp
compar
inhibit
preincub
particl
antibodi
effect
entri
driven
vsvg
figur
indic
epitop
recogn
conserv
ebov
ebov
ongo
evd
epidem
western
africa
unpreced
proport
call
largescal
assess
exist
option
antivir
intervent
develop
new
antivir
strategi
howev
amino
acid
substitut
uniqu
gp
current
circul
ebov
might
render
virus
nonsuscept
antivir
cellular
defens
target
gp
cellular
factor
promot
gpdriven
entri
present
studi
indic
scenario
appli
major
differ
host
cell
entri
driven
ebovgp
ebovgp
observ
gp
compar
suscept
blockad
inhibitor
antivir
host
cell
protein
ebovgp
contain
uniqu
amino
acid
substitut
rbd
may
alter
requir
host
cell
receptor
could
modul
viral
cell
tropism
result
suggest
case
entri
mediat
ebovgp
ebovgp
depend
express
cholesterol
transport
inhibit
compound
induc
accumul
endosom
cholesterol
moreov
express
endogen
axl
augment
gpdriven
entri
bind
directli
via
bridg
molecul
axl
ptdser
viral
envelop
promot
entri
driven
ebovgp
ebovgp
mld
gp
heavili
modifi
olink
glycan
requir
bind
certain
host
cell
lectin
observ
mld
ebovgp
contain
amino
acid
substitut
rel
mld
ebovgp
suggest
engag
cellular
lectin
might
differ
gp
howev
appreci
differ
observ
keep
compar
entri
factor
use
gp
facilit
entri
ident
spectrum
cell
line
deriv
bat
nhp
human
includ
cellderiv
macrophag
consist
differ
observ
reduct
ebovgp
transduct
cell
rel
mediat
ebovgp
effect
might
point
toward
subtl
differ
entri
factor
use
may
detect
assay
system
use
present
studi
remov
mld
endosom
cystein
proteas
catb
l
requir
subsequ
bind
gp
sever
studi
indic
vector
bear
ebovgp
well
authent
ebov
depend
activ
catbl
infecti
entri
cell
line
although
catbl
depend
seem
vari
ebolaviru
speci
activ
particular
proteas
dispens
ebov
spread
murin
model
present
studi
suggest
catbl
depend
extend
virus
current
circul
west
africa
howev
reduc
suscept
ebovgp
inhibitor
catl
rel
ebovgp
point
toward
minor
differ
proteas
requir
respect
gp
gp
ebov
cleav
proprotein
convertas
golgi
apparatu
infect
cell
evid
cleavag
ebovgp
obtain
data
shown
cleavag
product
surfac
unit
transmembran
unit
remain
coval
associ
via
disulphid
bond
one
could
specul
stabil
associ
might
differ
ebovgp
ebovgp
could
translat
differ
stabil
retrovir
particl
bear
gp
howev
compar
timeand
temperatur
depend
loss
infect
ebovgp
ebovgp
particl
observ
argu
substanti
differ
gp
stabil
although
disregard
gp
stabil
might
differ
context
retrovir
filovir
particl
interferoninduc
antivir
host
factor
neutral
antibodi
contribut
viral
control
infect
host
present
studi
suggest
ebov
variant
suscept
defens
mechan
express
ifitm
protein
compar
inhibit
host
cell
entri
driven
ebovgp
ebovgp
potenti
increas
endosom
cholesterol
level
moreov
entri
driven
gp
block
neutral
antibodi
obtain
human
evd
survivor
target
collect
result
observ
discuss
suggest
previous
present
circul
ebov
variant
might
use
similar
mechan
host
cell
entri
infect
similar
spectrum
target
cell
might
compar
suscept
inhibit
innat
adapt
immun
respons
supplementari
materi
avail
journal
infecti
diseas
onlin
http
jidoxfordjournalsorg
supplementari
materi
consist
data
provid
author
publish
benefit
reader
post
materi
copyedit
content
supplementari
data
sole
respons
author
question
messag
regard
error
address
author
